文献速递泌尿男性生殖肿瘤支持与姑息治疗

卡巴他赛对比阿比特龙或恩扎卢胺治疗转移性前列腺癌的生活质量:CARD随机研究分析

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
PubMed 文献 · Lancet Oncol · 2020-09-11

CARD研究在255例多西他赛及一种雄激素信号靶向药物治疗后的转移性去势抵抗性前列腺癌患者中,比较卡巴他赛与另一种雄激素信号靶向药物的生活质量。

核心结论

  • 卡巴他赛改善疼痛缓解、至疼痛进展时间、至症状性骨骼事件时间和EQ-5D-5L效用指数,与第二种雄激素信号靶向药物相比不降低生活质量。

研究设计与样本

  • CARD为随机、多中心、开放标签、4期研究,纳入62个中心、13个欧洲国家的255例转移性去势抵抗性前列腺癌患者。
  • 患者按1:1随机接受卡巴他赛(25 mg/m2 静脉每3周,泼尼松10 mg每日,粒细胞集落刺激因子)或阿比特龙(1000 mg口服每日一次+泼尼松5 mg每日两次)或恩扎卢胺(160 mg口服每日)。
  • 主要终点为影像学无进展生存;本文报告疼痛(BPI-SF第3项)、症状性骨骼事件及FACT-P和EQ-5D-5L患者报告结局。

临床怎么用

  • 对于多西他赛和一种雄激素信号靶向药物治疗后的转移性去势抵抗性前列腺癌患者,卡巴他赛可作为不降低生活质量的后续治疗选择。
  • 卡巴他赛在疼痛控制和延缓疼痛进展方面优于第二种雄激素信号靶向药物,支持其在此人群中的应用。

局限性

  • 研究为开放标签设计,可能影响患者报告结局的评估。
  • 疼痛反应和患者报告结局分析仅纳入有基线和至少一次基线后评估的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signalling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. METHODS: CARD was a randomised, multicentre, open-label, phase 4 study involving 62 clinical sites across 13 European countries. Patients (aged ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2) with confirmed metastatic castration-resistant prostate cancer were randomly assigned (1:1) by means of an interactive voice-web response system to receive cabazitaxel (25 mg/m2 intravenously every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1000 mg orally once daily plus 5 mg prednisone twice daily) or enzalutamide (160 mg orally daily). Stratification factors were ECOG performance status, time to disease progression on the previous androgen signalling-targeted inhibitor, and timing of the previous androgen signalling-targeted inhibitor. The primary endpoint was radiographic progression-free survival; here, we present more detailed analyses of pain (assessed using item 3 on the Brief Pain Inventory-Short Form [BPI-SF]) and symptomatic skeletal events, alongside preplanned patient-reported outcomes, assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and the EuroQoL-5 dimensions, 5 level scale (EQ-5D-5L). Efficacy analyses were done in the intention-to-treat population. Pain response was analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of BPI-SF item 3, and patient-reported outcomes (PROs) were analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of either FACT-P or EQ-5D-5L (PRO population). Analyses of skeletal-related events were also done in the intention-to-treat population. The CARD study is registered with ClinicalTrials.gov, NCT02485691, and is no longer enrolling. FINDINGS: Between Nov 17, 2015, and Nov 28, 2018, of 303 patients screened, 255 were randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126). Median follow-up was 9·2 months (IQR 5·6-13·1). Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035). Median time to symptomatic skeletal events was NE (95% CI 20·0-NE) with cabazitaxel and 16·7 months (10·8-NE) with abiraterone or enzalutamide (HR 0·59, 95% CI 0·35-1·01; log-rank p=0·050). Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21). There was a significant treatment effect seen in changes from baseline in EQ-5D-5L utility index score in favour of cabazitaxel over abiraterone or enzalutamide (p=0·030) but no difference between treatment groups for change from baseline in EQ-5D-5L visual analogue scale (p=0·060). INTERPRETATION: Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor. FUNDING: Sanofi.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Kramer G, Eymard JC, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol. 2020. PMID: 32926841. doi:10.1016/S1470-2045(20)30449-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。